||Role of Sympathetic Neurons in Development of Beta-Adrenergic Control of Ornithine Decarboxylase Activity in Peripheral Tissues: Effects of Neonatal 6-Hydroxydopamine Treatment.
Hou, Q. C. ;
Baker, F. E. ;
Seidler, F. J. ;
Bartolome, M. ;
Bartolome, J. ;
||Duke Univ. Medical Center, Durham, NC. Dept. of Pharmacology.;Health Effects Research Lab., Research Triangle Park, NC.
Sympathetic nervous system ;
Chemical sympathectomy ;
Ornithine decarboxylase ;
Beta adrenergic receptors ;
||Most EPA libraries have a fiche copy filed under the call number shown. Check with individual libraries about paper copy.
||Sympathetic neurons are thought to regulate the development of their postsynaptic targets. In the current study, the effects of sympathectomy with 6-hydroxydopamine in neonatal rats on the ontogeny of beta-receptor binding sites and their linkage to both cyclic AMP production and ornithine decarboxylase activity were examined. Cardiac norepinephrine levels and turnover were used to confirm the completeness and permanence of the lesion. The ability of isoproterenol, a beta-adrenergic agonist, to stimulate ornithine decarboxylase (a growth-related enzyme) in heart, lung and kidney, was reduced by neonatal sympathectomy; the effect persisted into young adulthood. The effect represented a selective uncoupling of enzyme activity from receptor activation as receptor binding capabilities were unaffected and the linkage of beta-receptors to cyclic AMP was enhanced. Comparison of the effects of peripheral sympathectomy with those of central lesions (intracisternal 6-hydroxydopamine) confirmed the importance of sympathetic nerve terminals in determining the coupling of the receptors to ornithine decarboxylase.
||Pub. in Jnl. of Developmental Physiology, v11 p139-146 Mar 89. Sponsored by Health Effects Research Lab., Research Triangle Park, NC.
|NTIS Title Notes
||Reprint: Role of Sympathetic Neurons in Development of Beta-Adrenergic Control of Ornithine Decarboxylase Activity in Peripheral Tissues: Effects of Neonatal 6-Hydroxydopamine Treatment.
||PC A03/MF A01